News

CADCA is asking our 5,000 community coalitions to spread the word to their communities that medicine abuse has become an epidemic. National Medicine Abuse Awareness Month promotes the

VTP-43742 is the Company’s wholly owned and first-in-class ROR?t inhibitor product candidate for the treatment of autoimmune disorders, potentially including psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis and

TruSight Tumor 15 is optimized for low input DNA from tissue preserved in formalin and paraffin. Illumina president Francis deSouza said: "In 2014, Illumina catalyzed the Actionable Genome

This final closing includes new strategic investments from AbbVie, WuXi PharmaTech, and Watson Fund. These new investors join the previously announced Accelerator IV syndicate, which includes Alexandria Venture

Enobosarm, a selective androgen receptor modulator (SARM), is the Company’s lead product candidate. GTx executive chairman Robert Wills said: "Additional endocrine directed therapies are needed for the treatment

The transaction was led by Rock Springs Capital Management and included other leading healthcare investors such as Fidelity Management and Research Company, Blackrock, funds, accounts managed by T.

The Johnson & Johnson Innovation Center in California facilitated the research agreement on behalf of the Janssen Disease Interception Accelerator. Under the terms of the agreement, UbiVac will

In July last year, the EC granted orphan designation for beloranib to treat Prader-Willi syndrome (PWS). Beloranib is being studied as a first-in-class obesity therapy that shows a

The product will be commercialized in Japan by Takeda Pharmaceutical Company Limited (Takeda). In Japan, glatiramer acetate was developed as an Unapproved New Drug by Teva Pharmaceutical K.K.,